Clinical trial · Interventional
Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer
Monocentric, Prospective Study Assessing the Feasibility to Use Resting Energy Expenditure by Indirect Calorimetry as Prognostic Marker of Tumoral Response to 1st Line Chemotherapy in Patients Suffering From Metastatic Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Protocol is not adapted to cancer pancreas disease as progression is very fast and patients stopped the study before 1st study assessment
Summary
Brief summary (as posted)
The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Measure of resting energetic expenditure | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- energetic expenditure measure
- description
- To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
- interventionNames
- Other: Measure of resting energetic expenditure
Primary outcomes (1)
- measure
- Resting energetic expenditure measurement by indirect calorimetry
- timeFrame
- 4 months
- description
- Unit measure : calorie per day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic metastatic cancer * Patient older than 18 years * Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel. * At least one measurable target lesion * Patient signed consent for Energie-Pancreas study participation Exclusion Criteria: * Other concomitant cancer * Major general status alteration ( Performance status = 3 or 4 at inclusion) * Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (\< 1 month), ongoing Healing, hyperthyroidism. * Smoker * Patient deprived of his liberty, under guardianship, curator. * Pregnant patient or breastfeeding * Claustrophobic patient
References
Publications (0)
Data not yet available